UK clinical trial regs are changing — here’s what’s happening
April 14, 2026 | HRA, MHRA, clinical trial
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
Change is coming to the UK’s clinical trials landscape – and it’s big. From 28 April 2026, updated Clinical Trial Regulations will come into play, representing the biggest shift in how we plan and deliver clinical trials in the UK in almost two decades.
The amendments, presented by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), were co-created in partnership with patients, researchers, and industry representatives, and represent a new era in UK clinical research.
The amendments bring the regulations into alignment with current culture. By promoting transparency and clarifying expectations, they aim to enhance participant safety, increase trial diversity, reduce researcher burden, speed up approvals, and position the UK as a trusted global research leader.
Here, we highlight some of the key updates and what they could mean in practice.
1. Updates to language and definitions
One of the most noticeable updates is the modernisation of terminology:
- Definitions have been updated to align with current language and tone:
- ‘Subject’ is now ‘participant’
- ‘Trial site’ is now ‘trial location’
- ‘Amendment’ is now ‘modification’
- There are now three distinct categories of trial modification:
- Substantial modifications
- Modification of an important detail
- Minor modifications
- The definition of Chief Investigator (CI) has been updated to refer to a ‘healthcare professional’. This change means a wider range of registered clinical professions are eligible to act as CIs. Individuals are required to be appropriately qualified through education, training, and experience.
2. Integrated statutory review
Combined Review (MHRA and a Research Ethics Committee) is a system that allows researchers to apply for ethics and regulatory approval at the same time. It has worked in practice for years, but now it’s embedded in the regulations. This means:
- A single integrated submission rather than separate parallel processes
- Faster, clearer decisions and improved communication between stakeholders
- Defined timelines and expectations for regulators and sponsors
For trial teams, this simplifies planning, reduces rework, and supports better alignment between regulatory and ethics considerations.
Initial applications will be made using IRAS. Learn more about the process and whether you need to create an account here.
3. Transparency is now a legal requirement
For the first time, the UK has statutory transparency obligations for all clinical trials of investigational medicinal products (CTIMPs):
- Trials must be publicly registered in a recognised registry
- Results summaries must be published within 12 months
- Plain-language summaries should be offered to participants
This is no longer optional best practice, but law. Trial teams should create standard operating procedures (SOPs) for trial registration, result sharing, and the process of developing timely participant-ready communications.
4. Expectations for trial start and oversight
The updated regulations introduce clearer expectations around when trials should begin and how they should be overseen once approved.
- Trial approvals will no longer remain valid indefinitely. Sponsors are expected to recruit the first UK participant within two years of approval, unless extended
- There is a clearer emphasis on risk-proportionate oversight, meaning the level of monitoring and governance should reflect the level of risk posed by the trial
- Regulatory expectations are more explicitly aligned with international Good Clinical Practice (GCP) principles
For trial teams, this means planning for faster trial start-up and ensuring oversight arrangements are proportionate to the risks involved.
Things to start thinking about
With April just around the corner, you may want to:
- Update your SOPs, playbooks, and templates to reflect the new terminology and processes
- Train your teams on the regulatory changes and what’s expected operationally
- Make sure your quality checks and oversight processes cover the new transparency and trial start rules
- Plan trial registrations and results reporting processes ahead of time
These changes don’t rewrite the basics of ethical, well-run trials, but they do clearly define expectations and bring the UK closer to global standards.
Don’t forget — on the same day as these updated regulations, the latest GCP Guidelines will also take effect in the UK. All clinical trials should comply with the principles of GCP.
If you or your team would like a short briefing slide deck or a practical checklist based on these changes, drop us a line — we are happy to help.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Promoting trust: Cuttsy+Cuttsy become a PIF Tick accredited agency
Cuttsy+Cuttsy join a host of noteworthy healthcare charities and institutions as one of the first healthcare communications agencies to receive the Patient Information Forum’s seal of approval – the PIF...
Listening to heads AND hearts in healthcare
We talk a lot about using emotions in healthcare communications, but not as much about the business intelligence(BI) behind it. Find out why it matters and why we are proud...
Does being an independent agency really matter?
With Cuttsy+Cuttsy ranked as #6 in the Independent Agencies listing from PM Live’s T40 Creative Healthcare Agencies 2021, Mathew Cutts reflects on what being ‘independent’ means to him.
Opening up about patient engagement
Read the third blog of the series looking at key barriers to effective patient engagement in pharma
Committing time to making meaningful connections – top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma
Key barriers to effective patient engagement in pharma, and how to fix them: Making engagement processes more patient friendly
In the first of this blog series, Patient Engagement Lead, Philippa Pristerà looks at making engagement processes more patient friendly
Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
Healthcare communications agency, Cuttsy+Cuttsy, has been awarded ‘We invest in People, Gold’ from Investors in People.
Cuttsy+Cuttsy marks its 10th anniversary with the launch of Cuttsy Cares
Healthcare communications agency, Cuttsy+Cuttsy, has announced the launch of Cuttsy Cares, in celebration of its 10th anniversary. The agency's charitable programme will deliver up to £10,000 to help improve the quality...
Caroline Benson and Colin Williams to Chair the PM Society from February 2020
For the first time both industry and agencies will be equally represented as the PM Society appoints a joint chair.
Clinical trials, Actually.
This Christmas, we’re thinking of the thousands of clinical trial volunteers across the UK, both patients and healthy participants. We have a lot to thank them for...